The diabetic treatment ‘Janumet XR’ exceeded the annual sales of KRW 10 billion within a year

The MSD Korea’s (CEO Dong-wook Hyun) DDP-4 inhibitor, the sitagliptin/metformin extended release ‘Janumet XR’, recorded the annual sales of KRW 10.3 billion (based on the UBIST’s outpatient prescription expenses) in 2014.

Along with the prescription raise with Janumet XR, the market of DDP-4 inhibitors and itagliptin/metformin extended releases is also growing.

According to the MSD Korea, mar...